The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR-34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …

Protein-coding genes comprise only 3% of the human genome, while the genes that are
transcribed into RNAs but do not code for proteins occupy majority of the genome. Once …

The majority of the human genome encodes RNAs that do not code for proteins. These non-
coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and …

In just over two decades since the discovery of the first microRNA (miRNA), the field of
miRNA biology has expanded considerably. Insights into the roles of miRNAs in …

Since the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA
biology has expanded substantially. miRNAs are involved and described as master …

Human cancers are characterized by a number of hallmarks, including sustained
proliferative signaling, evasion of growth suppressors, activated invasion and metastasis …

The discovery that noncoding components of the genome, including microRNA (miRNA or
miR), can contribute to the pathogenesis of cancer has led investigators to contemplate …

In April, Austin, Texas–based Mirna Therapeutics began dosing patients with MRX34, the
first microRNA (miRNA) mimic to reach phase 1 studies. Other companies in this emerging …

MicroRNAs (miRNAs) are a recently discovered category of small RNA molecules that
regulate gene expression at the post-transcriptional level. Accumulating evidence indicates …

Currently, one out of four deaths in the United States is due to cancer; therefore, every major
therapeutic advance in cancer has the potential to save many lives. One of the most …